Search Results - "Négrier, C."

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays by Horn, C., Négrier, C., Kalina, U., Seifert, W., Friedman, K. D.

“…Summary Essentials Performance of the one‐stage clotting (OSC) assay varies with the clotting activator used. Recombinant FIX‐albumin fusion protein (rIX‐FP)…”
Get full text

First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A by Hampton, K., Chowdary, P., Dunkley, S., Ehrenforth, S., Jacobsen, L., Neff, A., Santagostino, E., Sathar, J., Takedani, H., Takemoto, C. M., Négrier, C.

“…Background N8‐GP (turoctocog alfa pegol) is an extended half‐life glycoPEGylated recombinant factor VIII (FVIII) product developed for the prevention and…”
Get full text

A retrospective postlicensure survey of FEIBA efficacy and safety by DIMICHELE, D., NÉGRIER, C.

“…Patients with haemophilia who develop inhibitors have unique treatment needs; bypassing agents such as Factor Eight Inhibitor Bypassing Activity,…”
Get full text

Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF by Jousselme, E., Jourdy, Y., Rugeri, L., Négrier, C., Nougier, C.

“…Introduction The correct diagnosis and classification of VWD (von Willebrand disease) is crucial and must be optimized by including the collagen binding assay…”
Get full text

Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery by Négrier, C., Abdul Karim, F., Lepatan, L. M., Lienhart, A., López-Fernández, M. F., Mahlangu, J., Pabinger, I., Li, Y., Wolko, D., Voigt, C., Jacobs, I., Santagostino, E.

“…Introduction Recombinant factor IX fusion protein (rIX‐FP) has been developed to improve the pharmacokinetic (PK) profile of factor IX (FIX), allowing…”
Get full text

Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study by Négrier, C., Rothschild, C., Borg, J.-Y., Lambert, T., Claeyssens, S., Sanhes, L., Stieltjes, N., Bertrand, A., André, M.-H., Sié, P., Gruel, Y., Tellier, Z.

“…Background and Objectives A new fibrinogen concentrate Clottafact® was developed according to European guidelines on plasma‐derived products. A…”
Get full text

Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study by Négrier, C., Ducloy‐Bouthors, A.‐S., Piriou, V., De Maistre, E., Stieltjes, N., Borel‐Derlon, A., Colson, P., Picard, J., Lambert, T., Claeyssens, S., Boileau, S., Bertrand, A., André, M.‐H., Fourrier, F., Ozier, Y., Sié, P., Gruel, Y., Tellier, Z.

“…Background and Objectives A postauthorization safety study was performed between 2009 and 2012 to describe the use of Clottafact® in acquired fibrinogen…”
Get full text

Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study by Gringeri, A., Leissinger, C., Cortesi, P. A., Jo, H., Fusco, F., Riva, S., Antmen, B., Berntorp, E., Biasoli, C., Carpenter, S., Kavakli, K., Morfini, M., Négrier, C., Rocino, A., Schramm, W., Windyga, J., Zülfikar, B., Mantovani, L. G.

“…Summary Patients with haemophilia A and inhibitors are at high risk for severe bleeding, progression of joint disease and deterioration of health‐related…”
Get full text

Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels by Dargaud, Y., Hoffman, M., Lefrapper, L., Lin, F.‐C., Genty, A., Chatard, B., Marin, S., Négrier, C., Monroe, D. M.

“…Summary Objective Bleeding is the main complication of warfarin therapy, even patients with an international normalized ratio (INR) in the target range can…”
Get full text

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014 by Kessler, C, Oldenburg, J, Ettingshausen, C Escuriola, Tiede, A, Khair, K, Négrier, C, Klamroth, R

“…Inhibitor development is the most serious and challenging complication in the treatment of severe haemophilia A. Up to 38% of such patients develop inhibitors…”
Get full text

Recombinant activated factor VII in approved indications: Update on safety by Neufeld, E. J., Négrier, C., Benchikh el Fegoun, S., Cooper, D. L., Rojas‐Rios, A., Seremetis, S.

Get full text

SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies by Négrier, C., Lienhart, A., Numerof, R., Stephens, D., Wong, W. Y., Baghaei, F., Yee, T. T.

“…Summary Factor VIII Inhibitor Bypassing Activity (FEIBA) can effectively achieve haemostasis in haemophilia patients with inhibitors. Further evaluation of…”
Get full text

Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery by Rangarajan, S., Austin, S., Goddard, N. J., Négrier, C., Rodriguez-Merchan, E. C., Stephensen, D., Yee, T. T.

“…Summary A growing number of publications have described the efficacy and safety of FEIBA as a first‐line haemostatic agent for surgical procedures in…”
Get full text

FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry by Borg, J.-Y., Négrier, C., Durieu, I., Dolimier, E., Masquelier, A.-M., Lévesque, H.

“…Summary Factor VIII inhibitor bypass activity (FEIBA) is a recommended first‐line bypassing agent for bleeding episodes in patients with acquired haemophilia A…”
Get full text

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey by Poon, M‐C., D'Oiron, R., Von Depka, M., Khair, K., Négrier, C., Karafoulidou, A., Huth‐Kuehne, A., Morfini, M.

“…Background: Antibodies to glycoprotein (GP) IIb‐IIIa and/or HLA may render platelet transfusions ineffective to stop bleeding or to cover surgery in patients…”
Get full text

The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia by DARGAUD, Y., SIMPSON, H., CHEVALIER, Y., SCOAZEC, J. Y., HOT, A., GUYEN, O., BAGLIN, T., NÉGRIER, C.

“…Haemophilic arthropathy (HA) is one of the main complications of recurrent bleeding episodes in patients with severe haemophilia. However, the precise reasons…”
Get full text

Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency by PLANTIER, J. L., ROLLI, V., DUCASSE, C., DARGAUD, Y., ENJOLRAS, N., BOUKERCHE, H., NÉGRIER, C.

“…Background: Factor VIII (FVIII) and its activated form (FVIIIa) are subject to proteolysis that dampens their cofactor function. Among the proteases that…”
Get full text

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition by BERNTORP, E., COLLINS, P., D'OIRON, R., EWING, N., GRINGERI, A., NÉGRIER, C., YOUNG, G.

“…Assessing response to treatment with bypassing agents presents a substantial challenge in the treatment of patients with haemophilia and inhibitors. Rapid and…”
Get full text

Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate by NÉGRIER, C., ROTHSCHILD, C., GOUDEMAND, J., BORG, J. Y., CLAEYSSENS, S., ALESSI, M. C., JAFFRY, A. C., TEBOUL, C., PADRAZZI, B., WAEGEMANS, T.

“…Background: Inherited afibrinogenemia is a rare autosomal recessive disorder characterized by the absence or trace amounts of plasma fibrinogen inducing…”
Get full text

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA by A.N.L. Prezotti, K.J. Pasi, C. Négrier, M.V. Ragni, P. Georgiev, T. Lissitchkov, K. Salim, B. Mei, S. Andersson

Get full text